NCT00979849 - AZD8683 Single Ascending Dose Study | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Healthy Volunteers

Interventions

DRUG

AZD8683

Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.

DRUG

Placebo

Solution for nebulisation, inhaled

Trial Locations (1)

Unknown

Research Site, Philadelphia